Higham Claire, Abrahamsen Bo
Christie Hospital NHS Foundation Trust, Manchester, UK; University of Manchester, Manchester, UK.
Open Patient Data Exploratory Network, Department of Clinical Research, University of Southern Denmark, Odense, Denmark; Department of Medicine, Holbæk Hospital, Holbæk, Denmark; NDORMS, University of Oxford, Oxford, UK.
Best Pract Res Clin Endocrinol Metab. 2022 Mar;36(2):101614. doi: 10.1016/j.beem.2022.101614. Epub 2022 Jan 21.
Hormonal regulation plays a key role in determining bone mass in humans. Both skeletal growth and bone loss in health and disease is critically controlled by endocrine factors and low bone mass is a feature of both excess and deficiency of a broad range of hormones. This article explores the impact of diabetes and thyroid, parathyroid, sex steroid and growth hormone disorders on bone mass and fracture risk. Evidence for current management strategies is provided along with suggested practice points and gaps in knowledge for future research.
激素调节在决定人类骨量方面起着关键作用。无论是在健康状态还是疾病状态下，骨骼生长和骨质流失均受到内分泌因素的严格控制，而低骨量是多种激素分泌过多或不足的共同特征。本文探讨糖尿病以及甲状腺、甲状旁腺、性激素和生长激素紊乱对骨量和骨折风险的影响。文中提供了当前管理策略的证据，以及建议的实践要点和未来研究的知识空白。
